TY - JOUR
T1 - Local complement activation is associated with primary graft dysfunction after lung transplantation
AU - Kulkarni, Hrishikesh S.
AU - Ramphal, Kristy
AU - Ma, Lina
AU - Brown, Melanie
AU - Oyster, Michelle
AU - Speckhart, Kaitlyn N.
AU - Takahashi, Tsuyoshi
AU - Byers, Derek E.
AU - Porteous, Mary K.
AU - Kalman, Laurel
AU - Hachem, Ramsey R.
AU - Rushefski, Melanie
AU - McPhatter, Ja'Nia
AU - Cano, Marlene
AU - Kreisel, Daniel
AU - Scavuzzo, Masina
AU - Mittler, Brigitte
AU - Cantu, Edward
AU - Pilely, Katrine
AU - Garred, Peter
AU - Christie, Jason D.
AU - Atkinson, John P.
AU - Gelman, Andrew E.
AU - Diamond, Joshua M.
N1 - Funding Information:
We acknowledge Michelle Elvington, Kathy Liszewski, Dennis Hourcade, and Davide Scozzi for their thoughtful comments on the manuscript, Lynne Mitchell for sharing reagents, Jack Ferreira and Fuyi Liao for their technical assistance, all the members of the lung transplant programs for their input (including Chad A. Witt, Jennifer Alexander-Brett, Laneshia K. Tague, Rodrigo Vazquez-Guillamet, Varun Puri, and Ruben Nava), and our lung transplant recipients for their participation in the study. We acknowledge the following funding: National Center for Advancing Translational Sciences of the NIH under award KL2 TR002346 (to HSK, PI: Victoria J. Fraser); K08 HL148510 (to HSK); K23HL121406 (to JMD); K23HL116656 and R03HL135227 (to EC); R01 HL087115, K24 HL115354, and U01 HL145435 (to JDC); R01 GM99111 (to JPA); and R01HL094601 and P01AI116501 (to AEG). HSK was supported by the American Lung Association, Children’s Discovery Institute of Washington University and St. Louis Children’s Hospital (PD-FR-2020-867), and the Sharing Partnership for Innovative Research in Translation award through the Institute of Clinical and Translational Sciences at the Washington University (NIH/National Center for Advancing Translational Sciences grant UL1 TR002345). EC was funded by the Robert Wood Johnson Foundation under award AMFDP70640. RRH and AE were funded by the Cystic Fibrosis Foundation, and AEG was funded by the Barnes-Jewish Hospital Foundation. KP and PG were funded by The Danish Heart Foundation (16-R107-A6650-22966), the Danish Research Foundation of Independent Research (DFF-6110-00489), the Svend Andersen Research Foundation, and the Novo Nordisk Research Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Funding Information:
grants from GlaxoSmithKline and Bristol-Meyers Squibb and personal fees from Onspira and Magnolia. DK has a pending patent entitled “Compositions and methods for detecting CCR2 receptors” (application 15/611,577). JPA reports serving as a current consultant for Celldex Therapeutics, Clinical Pharmacy Services, Kypha Inc., Achillion Pharmaceuticals, and BioMarin Pharmaceutical and stock or equity options in Compliment Corporation, Kypha Inc., Gemini Therapeutics Inc., and AdMiRx Inc.
Funding Information:
This research was supported by the NIH, American Lung Association, Children's Discovery Institute, Robert Wood Johnson Foundation, Cystic Fibrosis Foundation, Barnes-Jewish Hospital Foundation, Danish Heart Foundation, Danish Research Foundation of Independent Research, Svend Andersen Research Foundation, and Novo Nordisk Research Foundation. We acknowledge Michelle Elvington, Kathy Liszewski, Dennis Hourcade, and Davide Scozzi for their thoughtful comments on the manuscript, Lynne Mitchell for sharing reagents, Jack Ferreira and Fuyi Liao for their technical assistance, all the members of the lung transplant programs for their input (including Chad A. Witt, Jennifer Alexander-Brett, Laneshia K. Tague, Rodrigo Vazquez-Guillamet, Varun Puri, and Ruben Nava), and our lung transplant recipients for their participation in the study. We acknowledge the following funding: National Center for Advancing Translational Sciences of the NIH under award KL2 TR002346 (to HSK, PI: Victoria J. Fraser); K08 HL148510 (to HSK); K23HL121406 (to JMD); K23HL116656 and R03HL135227 (to EC); R01 HL087115, K24 HL115354, and U01 HL145435 (to JDC); R01 GM99111 (to JPA); and R01HL094601 and P01AI116501 (to AEG). HSK was supported by the American Lung Association, Children's Discovery Institute of Washington University and St. Louis Children's Hospital (PD-FR-2020-867), and the Sharing Partnership for Innovative Research in Translation award through the Institute of Clinical and Translational Sciences at the Washington University (NIH/National Center for Advancing Translational Sciences grant UL1 TR002345). EC was funded by the Robert Wood Johnson Foundation under award AMFDP70640. RRH and AE were funded by the Cystic Fibrosis Foundation, and AEG was funded by the Barnes-Jewish Hospital Foundation. KP and PG were funded by The Danish Heart Foundation (16-R107-A6650-22966), the Danish Research Foundation of Independent Research (DFF-6110-00489), the Svend Andersen Research Foundation, and the Novo Nordisk Research Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Funding Information:
FUNDING. This research was supported by the NIH, American Lung Association, Children’s Discovery Institute, Robert Wood Johnson Foundation, Cystic Fibrosis Foundation, Barnes-Jewish Hospital Foundation, Danish Heart Foundation, Danish Research Foundation of Independent Research, Svend Andersen Research Foundation, and Novo Nordisk Research Foundation.
Publisher Copyright:
© 2020, Kulkarni et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.
PY - 2020/9/3
Y1 - 2020/9/3
N2 - BACKGROUND. The complement system plays a key role in host defense but is activated by ischemia/reperfusion injury (IRI). Primary graft dysfunction (PGD) is a form of acute lung injury occurring predominantly due to IRI, which worsens survival after lung transplantation (LTx). Local complement activation is associated with acute lung injury, but whether it is more reflective of allograft injury compared with systemic activation remains unclear. We proposed that local complement activation would help identify those who develop PGD after LTx. We also aimed to identify which complement activation pathways are associated with PGD. METHODS. We performed a multicenter cohort study at the University of Pennsylvania and Washington University School of Medicine. Bronchoalveolar lavage (BAL) and plasma specimens were obtained from recipients within 24 hours after LTx. PGD was scored based on the consensus definition. Complement activation products and components of each arm of the complement cascade were measured using ELISA. RESULTS. In both cohorts, sC4d and sC5b-9 levels were increased in BAL of subjects with PGD compared with those without PGD. Subjects with PGD also had higher C1q, C2, C4, and C4b, compared with subjects without PGD, suggesting classical and lectin pathway involvement. Ba levels were higher in subjects with PGD, suggesting alternative pathway activation. Among lectin pathway-specific components, MBL and FCN-3 had a moderate-to-strong correlation with the terminal complement complex in the BAL but not in the plasma. CONCLUSION. Complement activation fragments are detected in the BAL within 24 hours after LTx. Components of all 3 pathways are locally increased in subjects with PGD. Our findings create a precedent for investigating complement-targeted therapeutics to mitigate PGD.
AB - BACKGROUND. The complement system plays a key role in host defense but is activated by ischemia/reperfusion injury (IRI). Primary graft dysfunction (PGD) is a form of acute lung injury occurring predominantly due to IRI, which worsens survival after lung transplantation (LTx). Local complement activation is associated with acute lung injury, but whether it is more reflective of allograft injury compared with systemic activation remains unclear. We proposed that local complement activation would help identify those who develop PGD after LTx. We also aimed to identify which complement activation pathways are associated with PGD. METHODS. We performed a multicenter cohort study at the University of Pennsylvania and Washington University School of Medicine. Bronchoalveolar lavage (BAL) and plasma specimens were obtained from recipients within 24 hours after LTx. PGD was scored based on the consensus definition. Complement activation products and components of each arm of the complement cascade were measured using ELISA. RESULTS. In both cohorts, sC4d and sC5b-9 levels were increased in BAL of subjects with PGD compared with those without PGD. Subjects with PGD also had higher C1q, C2, C4, and C4b, compared with subjects without PGD, suggesting classical and lectin pathway involvement. Ba levels were higher in subjects with PGD, suggesting alternative pathway activation. Among lectin pathway-specific components, MBL and FCN-3 had a moderate-to-strong correlation with the terminal complement complex in the BAL but not in the plasma. CONCLUSION. Complement activation fragments are detected in the BAL within 24 hours after LTx. Components of all 3 pathways are locally increased in subjects with PGD. Our findings create a precedent for investigating complement-targeted therapeutics to mitigate PGD.
UR - http://www.scopus.com/inward/record.url?scp=85090265023&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.138358
DO - 10.1172/jci.insight.138358
M3 - Article
C2 - 32750037
AN - SCOPUS:85090265023
SN - 2379-3708
VL - 5
JO - JCI Insight
JF - JCI Insight
IS - 17
M1 - e138358
ER -